Kalaris Therapeutics Inc (KLRS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Andrew Oxtoby.
KLRS has IPO date of 2020-07-30, 14 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $109.78M.
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
